MYOBLOC 5000 UNIT — DIN 02252295
RIMABOTULINUMTOXINB : 5000 UNIT · SOLSTICE NEUROSCIENCES, LLC, A SUBSIDIARY OF MDD US OPERATIONS, LLC · SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED (UNRETURNED ANNUAL)
What is MYOBLOC?
MYOBLOC 5000 UNIT contains RIMABOTULINUMTOXINB : 5000 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02252295, held by SOLSTICE NEUROSCIENCES, LLC, A SUBSIDIARY OF MDD US OPERATIONS, LLC, supplied as SOLUTION for INTRAMUSCULAR administration. Health Canada currently lists it as cancelled (unreturned annual), status dated 29-Jan-2025. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
Is there a generic Botulinum Toxin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
7 holders have a Canadian DIN containing Botulinum Toxin, across 16 DINs, of which 12 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ABBVIE CORPORATION | 5 | 4 | BOTOX, BOTOX COSMETIC | Sourceable in Canada |
| MERZ PHARMACEUTICALS GMBH | 4 | 3 | XEOMIN, XEOMIN COSMETIC | Sourceable in Canada |
| IPSEN BIOPHARMACEUTICALS CANADA INC | 2 | 2 | DYSPORT THERAPEUTIC | Sourceable in Canada |
| HUGEL CANADA INC. | 2 | 1 | LETYBO | Sourceable in Canada |
| EVOLUS INCORPORATED | 1 | 1 | NUCEIVA | Sourceable in Canada |
| IPSEN BIOPHARMACEUTICALS CANADA INC SUITE 500 5050 Satellite Drive Mississauga Ontario Canada L4W 0G1 | 1 | 1 | DYSPORT AESTHETIC | Sourceable in Canada |
| SOLSTICE NEUROSCIENCES, LLC, A SUBSIDIARY OF MDD US OPERATIONS, LLC | 1 | 0 | MYOBLOC | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 5000 UNIT |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAMUSCULAR |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Botulinum Toxin |
|---|---|
| ATC code | M03AX01 |
| AHFS class | 12:20.20.24 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02252295 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2252295 |
| Brand name | MYOBLOC |
| Generic / active ingredient | RIMABOTULINUMTOXINB : 5000 UNIT |
| Market authorization holder | SOLSTICE NEUROSCIENCES, LLC, A SUBSIDIARY OF MDD US OPERATIONS, LLC |
| Health Canada schedule | Prescription |
| ATC code | M03AX01 |
| ATC anatomical main group | M — Musculo-skeletal system |
| ATC therapeutic subgroup | M03AX |
| Current status | CANCELLED (UNRETURNED ANNUAL) |
| Status date | 29-Jan-2025 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
12 of 16 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| BOTOX | 200 UNIT | POWDER FOR SOLUTION | ABBVIE CORPORATION | MARKETED | 02531585 |
| BOTOX | 50 UNIT | POWDER FOR SOLUTION | ABBVIE CORPORATION | MARKETED | 02531577 |
| BOTOX | 100 UNIT | POWDER FOR SOLUTION | ABBVIE CORPORATION | MARKETED | 01981501 |
| BOTOX COSMETIC | 100 UNIT | POWDER FOR SOLUTION | ABBVIE CORPORATION | MARKETED | 02243721 |
| DYSPORT AESTHETIC | Strength | Powder For Solution | IPSEN BIOPHARMACEUTICALS CANADA INC SUITE 500 5050 Satellite Drive Mississauga Ontario Canada L4W 0G1 | MARKETED | 02387735 |
| DYSPORT THERAPEUTIC | 300 UNIT | POWDER FOR SOLUTION | IPSEN BIOPHARMACEUTICALS CANADA INC | MARKETED | 02460203 |
| DYSPORT THERAPEUTIC | 500 UNIT | POWDER FOR SOLUTION | IPSEN BIOPHARMACEUTICALS CANADA INC | MARKETED | 02456117 |
| LETYBO | 100 UNIT | POWDER FOR SOLUTION | HUGEL CANADA INC. | MARKETED | 02528142 |
| NUCEIVA | 100 UNIT | POWDER FOR SOLUTION | EVOLUS INCORPORATED | MARKETED | 02480158 |
| XEOMIN | 50 UNIT | POWDER FOR SOLUTION | MERZ PHARMACEUTICALS GMBH | MARKETED | 02371081 |
2 · Same class — other molecules in ATC M03AX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Botulinum Toxin | BOTOX · BOTOX COSMETIC · DYSPORT AESTHETIC · DYSPORT THERAPEUTIC · +5 more | 16 | 12 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC M03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| M03AC | Atracurium · Cisatracurium · Doxacurium Chloride · Gallamine · Mivacurium Chloride · +3 more | 44 | 7 |
| M03AB | Suxamethonium | 9 | 3 |
| M03AA | Dimethyltubocurarine · Tubocurarine | 3 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled (unreturned annual) in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.